Chronic Hepatitis B Virus Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Chronic Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Chronic
Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030"
report delivers an in-depth understanding of the Chronic Hepatitis B Virus ,
historical and forecasted epidemiology as well as the Chronic Hepatitis B Virus
market trends in the United States, EU5 (Germany, Spain, Italy, France, and
United Kingdom) and Japan.
1. In 2016, WHO set the target of eliminating
chronic HBV as a public health threat by 2030. Elimination of HBV by 2030 will
require diagnosis of 90% of people infected with HBV and antiviral treatment of
80% of diagnosed people eligible for therapy.
2. As per DelveInsight’s analysts, the t otal prevalent cases of CHB were 5,797,240 in
2017, which are expected to rise during the study period (2017-2030).
3. Among the 7MM, the United States accounted for
nearly 39% of the total prevalent population of CHB in the year 2017.
4. Low diagnosis rate observed across the 7MM and
possible factors could be people infected with CHB often have no symptoms and
not aware about CHB and also there is overall lack of awareness surrounding HBV
necessitates provider education on cut-off values for abnormal levels of
alanine aminotransferase (ALT)
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
·
The report covers
the descriptive overview of Chronic Hepatitis B Virus , explaining its causes,
signs and symptoms, pathophysiology, diagnosis and currently available
therapies
·
Comprehensive
insight has been provided into the Chronic Hepatitis B Virus epidemiology and
treatment in the 7MM
·
Additionally, an
all-inclusive account of both the current and emerging therapies for Chronic
Hepatitis B Virus are provided, along with the assessment of new therapies,
which will have an impact on the current treatment landscape
·
A detailed review
of Chronic Hepatitis B Virus market; historical and forecasted is included in
the report, covering drug outreach in the 7MM
·
The report
provides an edge while developing business strategies, by understanding trends
shaping and driving the global Chronic Hepatitis B Virus market
Chronic
Hepatitis B Virus is a life-threatening and one of the most
common liver infections around the globe. It is caused by the hepatitis B virus
(HBV), which attacks and injures the liver. HBV can cause both acute and
chronic disease. If an individual suffers from HBV infection which lasts more
than six months, then the infection becomes chronic. Having chronic hepatitis B
(CHB) increases the risk of developing liver failure, liver cancer or
cirrhosis. HBV is mostly transmitted through blood and infected bodily fluids.
It can be passed to others through direct contact with blood, unprotected sex,
use of illegal drugs, unsterilized or contaminated needles.
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
The Chronic Hepatitis B Virus epidemiology
division provides insights about historical and current patient pool and forecasted
trend for every seven major countries. The Chronic Hepatitis B Virus
epidemiology data are studied through all possible division to give a better
understanding of the Disease scenario in 7MM. The Chronic Hepatitis B Virus
epidemiology segment covers the epidemiology data in the US, EU5 countries
(Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It
also helps to recognize the causes of current and forecasted trends by
exploring numerous studies, survey reports and views of key opinion leaders.
·
GlaxoSmithKline
·
Ionis Pharma
·
Janssen Sciences
·
Hoffmann-La Roche
·
Gilead Sciences
·
Assembly Biosciences
·
GSK3228836
·
JNJ-56136379 And
JNJ-3989 ± JNJ-6379 +NUC
·
RG7907 + RG7854 +
NUC
·
Selgantolimod
(GS-9688)
·
Vebicorvir
(ABI-H0731) +NUC
·
And Many Others
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
1. Key Insights
2. Executive Summary of Chronic
Hepatitis B Virus
3. Competitive Intelligence Analysis
for Chronic Hepatitis B Virus
4. Chronic Hepatitis B Virus : Market
Overview at a Glance
5. Chronic Hepatitis B Virus : Disease
Background and Overview
6. Patient Journey
7. Chronic Hepatitis B Virus
Epidemiology and Patient Population
8. Treatment Algorithm, Current
Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Chronic Hepatitis
B Virus Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Chronic Hepatitis B Virus: Seven
Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
of Chronic Hepatitis B Virus
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
Media Contact
Company Name: DelveInsight
Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website:https://www.delveinsight.com/
Comments
Post a Comment